Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $130...
United States
The firm is representing Unicycive Therapeutics, Inc. (Nasdaq:
UNCY), a clinical-stage biotechnology company developing therapies
for patients with kidney disease, in its $130 million private
placement.
The funding is being led by Vivo Capital with participation from
RA Capital, BVF Partners, Logos Capital, and is supported by
existing investors Nantahala Capital Partners and Rosalind Advisors
Inc.
The deal was led by Jeff Fessler, co-leader of Sheppard
Mullin's Life Sciences Industry Team and associate Seth
Lemings.
Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
